Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tislelizumab in Combination With Lenalidomide in in Patients With Relapsed or Refractory Elderly Patients With Non-GCB Diffuse Large B Cell Lymphoma: a Prospective Phase Ib/II, Multicentre, Open-label, Single-arm Trial

NCT04796857 is registered in ClinicalTrials.gov with Huiqiang Huang as lead sponsor.

NCT NCT04796857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04796857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tislelizumab in Combination With Lenalidomide in in Patients With Relapsed or Refractory Elderly Patients With Non-GCB Diffuse Large B Cell Lymphoma: a Prospective Phase Ib/II, Multicentre, Open-label, Single-arm Trial
Lead sponsor
Huiqiang Huang
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2021
Completion date
March 31, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive anaplastic large cell lymphoma, ebv-positive dlbcl, nos, follicular lymphoma grade iiib, high-grade b-cell lymphoma, non-gcb/abc diffuse large b-cell lymphoma, transformed lymphoma